Fluvoxamine vs Placebo and Time to Sustained Recovery From Mild or Moderate COVID-19

Susanna Naggie, MD, vice dean for research at Duke University's School of Medicine, discusses the ACTIV-6 trial of fluvoxamine for outpatient treatment of COVID-19 and outlines the role of platform trials during the pandemic. Hosted by JAMA Deputy Editor and Editorial Director for Equity Preeti Malani, MD, MSJ. Related Content: Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19